BioGaia Logo

BioGaia

A healthcare and biotechnology company developing clinically proven probiotic products.

BIOG | ST

Overview

Corporate Details

ISIN(s):
SE0000470395 (+2 more)
LEI:
549300UBUJOY2L7TT361
Country:
Sweden
Address:
Box 3242, 103 64 Stockholm

Description

BioGaia is a healthcare and biotechnology company that is a world leader in probiotics. A pioneer in microbiome research for over 30 years, the company develops, markets, and sells a range of clinically proven probiotic products. Its portfolio is centered on its patented probiotic strain, Lactobacillus reuteri. These products, typically offered as food supplements, are designed to support the health and well-being of consumers at all stages of life.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-22 08:00 Swedish 1.6 MB
2025-10-22 08:00 English 1.5 MB
2025-08-22 17:30
Extra bolagsstämma i BioGaia
Swedish 149.3 KB
2025-08-22 17:30
Extraordinary General Meeting of BioGaia
English 71.0 KB
2025-07-25 09:31
Kallelse till extra bolagsstämma i BioGaia AB (publ)
Swedish 169.8 KB
2025-07-25 09:31
Notice to attend the Extraordinary General Meeting of BioGaia AB (publ)
English 199.0 KB
2025-07-18 08:01 Swedish 20.6 MB
2025-07-18 08:01 English 18.4 MB
2025-06-18 14:20 Swedish 10.0 KB
2025-05-30 11:00
Förändrat antal röster i BioGaia AB (publ)
Swedish 261.2 KB
2025-05-30 11:00
Change in the number of votes in BioGaia AB (publ)
English 231.4 KB
2025-05-21 14:04 Swedish 10.0 KB
2025-05-20 13:01 Swedish 10.7 KB
2025-05-14 16:43 Swedish 10.0 KB
2025-05-12 16:39 Swedish 10.0 KB

Automate Your Workflow. Get a real-time feed of all BioGaia filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BioGaia

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BioGaia via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-05-08 Barbro Fridén Other Buy 188 19,627.20 SEK
2024-09-13 Linda Hägglund Other Sell 2,000 233,800.00 SEK
2024-09-12 Linda Hägglund Other Sell 994 115,502.80 SEK
2024-09-12 Linda Hägglund Other Sell 6 697.80 SEK
2024-06-10 Outi Armstrong Other Buy 1,000 125,400.00 SEK
2023-08-02 Anthon Jahreskog Other Buy 481 51,515.10 SEK
2023-08-02 Anthon Jahreskog Other Buy 169 18,083.00 SEK

Peer Companies

Aldeyra Therapeutics, Inc. Logo
Develops medications for immune-mediated ocular and systemic diseases.
United States of America
ALDX
Alector, Inc. Logo
Clinical-stage biotech using immuno-neurology to treat neurodegenerative diseases.
United States of America
ALEC
ALK-Abelló Logo
A pharmaceutical company specializing in allergy prevention, diagnosis, and treatment.
Denmark
ALK
Alkaloid AD Logo
Manufactures generic pharmaceuticals, cosmetics, and chemical products.
North Macedonia
ALK
Alkermes plc. Logo
Develops and commercializes medicines for central nervous system (CNS) diseases.
United States of America
ALKS
Allarity Therapeutics, Inc. Logo
A clinical-stage biopharma using diagnostics to develop targeted cancer therapies.
United States of America
ALLR
ALLERGY THERAPEUTICS PLC Logo
Immunology company developing aluminum-free vaccines and therapies for allergies.
United Kingdom
AGY
Alligator Bioscience Logo
Clinical-stage biotech developing tumor-directed immuno-oncology antibody drugs.
Sweden
ATORX
Allogene Therapeutics, Inc. Logo
Develops off-the-shelf allogeneic CAR T therapies for cancer and autoimmune diseases.
United States of America
ALLO
Almirall S.A. Logo
Global biopharmaceutical company specializing in medical dermatology and skin health.
Spain
ALM

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.